Literature DB >> 27659931

Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis.

Tatiana De Los Ríos1, Juan Pérez-Martínez2, Jose Portoles3, Monika Lichodziejewska-Niemierko4, Maite Rivera5, Michał Nowicki6, Andrzej Książek6, Ana María Tato7, Christine Bohnhorst8, Mariano Feriani9.   

Abstract

Interference of conventional peritoneal dialysis fluids (cPDFs) with peritoneal membrane cell functions may be attributed to the dialysis fluid's low pH, high glucose concentration, and/or the presence of glucose degradation products (GDPs), the last of which leads to higher levels of advanced glycation end-products (AGEs). It has been suggested that the peritoneal membrane might be better preserved by using biocompatible solutions, including cancer antigetn 125 (CA125). This prospective, open-label, multicentre, randomized, controlled, cross-over phase IV study compared the in vivo biocompatibility of a neutral-pH, low-GDP peritoneal dialysis (PD) solution (balance) with a cPDF in automated PD (APD) patients. Our study revealed a significantly increased appearance rate and concentration of CA125 in the peritoneal effluent of APD patients treated with the neutral-pH, low-GDP solution balance versus a conventional PD solution.
Copyright © 2016 International Society for Peritoneal Dialysis.

Entities:  

Keywords:  Biocompatibility; cancer antigen 125; pH neutral; peritoneal dialysis fluids; residual renal function; ultrafiltration

Mesh:

Substances:

Year:  2016        PMID: 27659931      PMCID: PMC5033636          DOI: 10.3747/pdi.2015.00010

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  15 in total

Review 1.  Nightly intermittent peritoneal dialysis prescription and power.

Authors:  G Woodrow
Journal:  Contrib Nephrol       Date:  1999       Impact factor: 1.580

2.  Glucose degradation products in peritoneal dialysis fluids: how they can be avoided.

Authors:  A Wieslander; T Linden; P Kjellstrand
Journal:  Perit Dial Int       Date:  2001       Impact factor: 1.756

3.  Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.

Authors:  Sejoong Kim; Jieun Oh; Suhnggwon Kim; Wookyung Chung; Curie Ahn; Sung Gyun Kim; Kook-Hwan Oh
Journal:  Nephrol Dial Transplant       Date:  2009-03-03       Impact factor: 5.992

4.  Peritoneal mononuclear cell differentiation and cytokine production in intermittent and continuous automated peritoneal dialysis.

Authors:  E Wrenger; C Baumann; M Behrend; E Zamore; R Schindler; R Brunkhorst
Journal:  Am J Kidney Dis       Date:  1998-02       Impact factor: 8.860

5.  Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels.

Authors:  S Jones; C J Holmes; R T Krediet; R Mackenzie; D Faict; A Tranaeus; J D Williams; G A Coles; N Topley
Journal:  Kidney Int       Date:  2001-04       Impact factor: 10.612

6.  Longitudinal follow-up of CA125 in peritoneal effluent.

Authors:  M M Ho-dac-Pannekeet; J K Hiralall; D G Struijk; R T Krediet
Journal:  Kidney Int       Date:  1997-03       Impact factor: 10.612

7.  Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.

Authors:  Cheuk-Chun Szeto; Kai-Ming Chow; Christopher Wai-Kei Lam; Chi-Bon Leung; Bonnie Ching-Ha Kwan; Kwok-Yi Chung; Man-Ching Law; Philip Kam-Tao Li
Journal:  Nephrol Dial Transplant       Date:  2006-09-27       Impact factor: 5.992

Review 8.  The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?

Authors:  Jeffrey Perl; Sharon J Nessim; Joanne M Bargman
Journal:  Kidney Int       Date:  2011-01-19       Impact factor: 10.612

9.  The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.

Authors:  John D Williams; Nicholas Topley; Kathrine J Craig; Ruth K Mackenzie; Monika Pischetsrieder; Cristina Lage; Jutta Passlick-Deetjen
Journal:  Kidney Int       Date:  2004-07       Impact factor: 10.612

10.  Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report.

Authors:  Yong-Lim Kim; Junyoung Do; Sun-Hee Park; Kyuhyang Cho; Jongwon Park; Kyungwoo Yoon; Dong-Kyu Cho; Eun-Gyui Lee; In-San Kim
Journal:  Nephrology (Carlton)       Date:  2003-10       Impact factor: 2.506

View more
  1 in total

1.  Biocompatible dialysis fluids for peritoneal dialysis.

Authors:  Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho
Journal:  Cochrane Database Syst Rev       Date:  2018-10-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.